News & Events
November 23, 2020
Collaboration with Ionis Pharmaceuticals on new therapies for neurodevelopment disorders
We’re thrilled to have entered into a sponsored research agreement with Ionis Pharmaceuticals, the leading experts on antisense technology. The partnership will be between Ionis and the Prosser and Davidson labs at Penn and CHOP, respectively, and is focused on testing a new approach to treat STXBP1 disorders using antisense oligonucleotides.
Tags:
Related Posts
- Ben co-Chairing Cardiac Regulatory Mechanisms GRC ( March 5, 2024 )
- Scientist Shifts Focus to Daughter’s Rare Disease ( April 17, 2023 )
- $25 Million Gift to Penn Medicine and Children’s Hospital of Philadelphia Establishes Center for Epilepsy and Neurodevelopmental Disorders ( February 8, 2023 )
- Our Leducq Cytoskeletal Network has begun! ( January 1, 2021 )
- Congrats Julie on your cover story in Circ Res! ( January 22, 2020 )
- Matt’s work on microtubules in diastolic dysfunction published in Circulation! ( November 22, 2019 )
- Press for Chen et al., Nature Med 2018 ( September 29, 2018 )
- Prosser lab work published in Nature Medicine! ( June 11, 2018 )
- Ben wins AHA Outstanding Early Career Investigator Award ( July 25, 2017 )
- Welcome Alex S! ( March 23, 2017 )
About the Author
The Author has not yet added any info about himself
Recent Posts
- Ben co-Chairing Cardiac Regulatory Mechanisms GRC
- Scientist Shifts Focus to Daughter’s Rare Disease
- $25 Million Gift to Penn Medicine and Children’s Hospital of Philadelphia Establishes Center for Epilepsy and Neurodevelopmental Disorders
- Our Leducq Cytoskeletal Network has begun!
- Collaboration with Ionis Pharmaceuticals on new therapies for neurodevelopment disorders
Recent Comments
No comments to show.